Sutro Biopharma (STRO) Accumulated Depreciation (2017 - 2025)

Sutro Biopharma has disclosed Accumulated Depreciation across 9 years of filings, most recently posting $27.4 million for Q4 2025.

• Accumulated Depreciation for Q4 2025 came in at $27.4 million, down 43.75% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.4 million (down 43.75% YoY), and the FY2025 annual result was $27.4 million, down 43.75% from the prior year.
• Accumulated Depreciation came in at $27.4 million for Q4 2025 at Sutro Biopharma, down from $48.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $48.6 million in Q4 2024 to a low of $27.4 million in Q4 2025.
• The 5-year median for Accumulated Depreciation is $37.9 million (2022), against an average of $37.9 million.
• Across the five-year window, Accumulated Depreciation rose 15.34% in 2024 and slumped 43.75% in 2025, its largest moves.
• Sutro Biopharma's Accumulated Depreciation stood at $33.4 million in 2021, then rose by 13.4% to $37.9 million in 2022, then climbed by 11.23% to $42.2 million in 2023, then rose by 15.34% to $48.6 million in 2024, then plunged by 43.75% to $27.4 million in 2025.
• The last three Accumulated Depreciation figures came in at $27.4 million (Q4 2025), $48.6 million (Q4 2024), and $42.2 million (Q4 2023), per Business Quant data.